Importance of erythropoetin receptor expression in tumour tissue for the clinical course of breast cancer.
Adverse outcomes in breast cancer patients treated with recombinant human erythropoietin (rhEpo) have been linked to the expression of Epo-receptors (EpoR) in cancer cells, although limited data on the clinical significance of these observations are available. Tissue samples from 107 patients with breast cancer who did not receive rhEpo and from 12 patients with benign lesions were retrospectively analysed for EpoR expression by RT-PCR and Western blot, and the results were correlated to clinical and demographic data. While EpoR levels were not linked to anaemia or inflammation, they were positively associated with progesterone and oestrogen receptor status. Patients with increased EpoR-mRNA expression had a higher local cancer recurrence rate (p=0.021), however, no significant difference in overall survival was observed. Since EpoR expression is associated with hormone receptor positivity and decreased locoregional disease control, this parameter characterises a specific cancer phenotype rather than being a negative predictor itself.